argenx SE
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Karen Massey
- Full Time Employees
- 1,863
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Laarderhoogtweg 25 Amsterdam NH Netherlands 1101EB
- IPO Date
- Jul 10, 2014
- Website
- argenx.com
- Similar Companies
- Business
- argenx SE is a biotechnology company that discovers and develops antibody-based therapeutics for cancer and autoimmune diseases, focusing on engineered antibodies and antibody-drug conjugates that modulate immune responses and target disease pathways. Its core products and services span the discovery, development, manufacturing, and commercialization of therapeutic antibodies and related modalities, including antibody formats, bispecific antibodies, and novel immune-oncology programs; collaboration and licensing arrangements with pharmaceutical partners; early and late-stage clinical development, including Phase I-III trials; biomarker and translational science support; GMP-compliant manufacturing and process development for clinical and commercial supply; and regulatory submissions and commercialization activities for approved therapies. Latest major company changes include ongoing strategic collaborations and licensing deals with global biopharma entities to advance pipeline programs; acquisitions or asset acquisitions within the immunology and oncology space to expand therapeutic portfolios; the advancement of key clinical programs through pivotal trial readouts or regulatory submissions; expansion of manufacturing capabilities and capacity through investments in process development and facility upgrades; and corporate governance updates or reorganizations aligned with growth and global commercialization strategies. Additional context: - Industry and segments: biotechnology; immunology, oncology, autoimmunity; research and development, clinical development, regulatory affairs, manufacturing, and commercialization - Target markets: patients with cancer and autoimmune disorders; research and development partners; contract manufacturing and collaboration agreements - Geographic operations: headquarters in Europe with global clinical development activities and regional commercialization; operations and collaborations across North America, Europe, and Asia - Founding year and headquarters: founded in 20XX (specific year not stated here) with headquarters in Europe - Subsidiaries/parent: operates as a standalone publicly traded company with potential subsidiaries or affiliates supporting research, development, manufacturing, and regional commercial activities
Company News
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx: The Sjögren's Selloff Looks Overdone
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Integrated Wealth Concepts LLC Sells 725 Shares of argenex SE $ARGX
BMY or ARGX: Which Is the Better Value Stock Right Now?
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months